Who is the CEO of Star Imaging and Path Lab Ltd?
- Answer Field
-
The CEO of Star Imaging and Path Lab Ltd is Pawan Gupta.
BAJAJ BROKING
Star Imaging and Path Lab Limited, incorporated in 2004, is a healthcare diagnostics company offering a broad spectrum of medical testing services. It provides imaging diagnostics such as X-rays, CT scans, MRIs, 4D and 5D ultrasounds, and digital mammography. Alongside these, the company also delivers pathology services including haematology, microbiology, histopathology, and PCR-based testing. Its diagnostic capabilities cover routine as well as specialised testing, positioning the company to serve both individuals and institutional healthcare providers.
The company operates across multiple regions and employs 209 full-time staff, including executive directors, as of September 30, 2024. With a focus on delivering accurate and timely reports, it utilises advanced diagnostic technology and trained professionals. Its continued investment in infrastructure and service quality may support its operations in the evolving healthcare sector. Investors considering the Medistep Healthcare IPO may take note of such operational models as they assess sector trends and peer benchmarks.
For more details, visit the Star Imaging and Path Lab IPO page.
Details | Information |
IPO Date | August 8, 2025 to August 12, 2025 |
Issue Size | 48,92,000 shares (aggregating up to ₹69.47 Cr) |
Price Band | ₹135 to ₹142 per share |
Lot Size | 1000 shares |
Listing At | BSE SME |
Market Maker | Share India Securities Limited |
Repayment/prepayment of certain borrowings availed of by the Company
To Meet Working Capital Requirements
Funding the Capital Expenditure towards purchase of Refurbished Medical Equipment in running facilities
General Corporate Purpose
Event | Date |
---|---|
IPO Open Date | Fri, Aug 8, 2025 |
IPO Close Date | Tue, Aug 12, 2025 |
Tentative Allotment | Wed, Aug 13, 2025 |
Initiation of Refunds | Thu, Aug 14, 2025 |
Credit of Shares to Demat | Thu, Aug 14, 2025 |
Tentative Listing Date | Mon, Aug 18, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on August 12, 2025 |
₹135 to ₹142 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,84,000 |
Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,84,000 |
S-HNI (Min) | 3 | 3,000 | ₹4,26,000 |
S-HNI (Max) | 7 | 7,000 | ₹9,94,000 |
B-HNI (Min) | 8 | 8,000 | ₹11,36,000 |
Log in to Your Trading Account: Access your trading account through your broker’s platform.
Navigate to the IPO Section: Go to the IPO section to view active IPO listings.
Select Star Imaging and Path Lab IPO: Find "Star Imaging and Path Lab IPO" and click on the ‘Apply’ button.
Enter Application Details: Specify the number of lots (minimum lot size: 1000 shares) and the bid price within the range of ₹135 to ₹142 per share.
Provide Your UPI ID: Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit: Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on August 12, 2025, to complete your application process.
Additional Read- How to Apply for the Star Imaging and Path Lab IPO?
Total Assets: Grew from ₹61.23 crore in FY24 to ₹98.16 crore as of March 2025.
Total income: Reached ₹83.79 crore in FY25.
Profit After Tax (PAT): Stood at ₹15.96 crore for March 2025.
Net Worth: Recorded at ₹47.15 crore in FY25.
Reserves and Surplus: Recorded at ₹33.65 crore (March 2025), growing steadily over the years.
EBITDA: Stood at ₹28.60 crore in March 2025.
The company has demonstrated consistent expansion in its asset base, reflecting operational scaling and improved financial capacity.
Revenue generation has shown an upward trend, indicating strong demand for the company’s diagnostic and imaging services.
Profitability has remained steady, supported by efficient cost management and service diversification.
The company’s financial strength is underpinned by an increase in net worth, suggesting improved shareholder value and business stability.
Reserves and surplus have seen steady growth, which may support future investments and operational resilience.
Operational performance has remained stable, with earnings showing the ability to support ongoing business needs and potential strategic growth initiatives.
The healthcare diagnostics sector is highly competitive, and the company may face pricing and market share pressure from both organised and unorganised players.
The business is dependent on continuous investment in technology and medical equipment, which could impact margins if not managed efficiently or if returns are delayed.
The company’s diverse service offerings in radiology, pathology, and specialised testing position it to cater to a wide base of healthcare needs across various regions.
Planned use of IPO proceeds for debt repayment, capital equipment purchases, and working capital may strengthen operations and support future expansion.
KPI | Values |
ROE | 40.65% |
ROCE | 29.92% |
Debt/Equity | 0.69 |
RoNW | 40.65% |
PAT Margin | 19.10% |
EBITDA Margin | 34.22% |
Price to Book Value | 4.07 |
Registrar |
Lead Manager(s) |
---|---|
Kfin Technologies Limited | Share India Capital Services Private Limited |
Star Imaging & Path Lab Ltd. 4B/4, Tilak Nagar, Near Sant Pura, Tilak Nagar West Delhi, New Delhi, New Delhi, 110018
Phone: +91 9990019189
Email: cs@starimaging.in
Website: https://www.starimaging.in/
Star Imaging and Path Lab Limited operates as a multi-service diagnostics company with offerings in radiology, pathology, and routine as well as specialised testing. Its services are supported by diagnostic infrastructure and a team of trained professionals, with operations spread across multiple regions. As of September 2024, the company had over 200 full-time staff members contributing to its operational framework.
The upcoming IPO has outlined specific objectives including debt repayment, working capital support, and purchase of refurbished medical equipment. The company’s financial indicators and expansion efforts reflect a phase of active business planning. Investors reviewing the offering may consider the broader healthcare diagnostics landscape, the company's current positioning, and sectoral benchmarks when making assessments.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Star Imaging and Path Lab IPO.
Share this article:
No result found
The CEO of Star Imaging and Path Lab Ltd is Pawan Gupta.
The IPO will open for subscription on August 8, 2025, and will close on August 12, 2025.
Star Imaging and Path Lab Ltd is engaged in providing diagnostic services, including radiology (X-rays, MRIs, CT scans, ultrasounds) and pathology (blood tests, microbiology, histopathology). It caters to individuals and healthcare institutions. The business operates across multiple regions and continues to invest in equipment and workforce. Its sustainability depends on factors like service demand, healthcare spending trends, and ongoing investments in diagnostic technology and infrastructure.
The issue size is 48,92,000 equity shares, aggregating up to ₹69.47 crore.
‘Pre-apply’ allows investors to submit their IPO application before the official subscription window opens. The order is queued and processed as soon as the IPO opens, helping investors avoid last-minute delays.
You will receive a confirmation from your broker or investing platform once the UPI mandate is approved and your IPO order is successfully placed. It is essential to approve the mandate before the 5 PM cut-off on August 12, 2025.
The minimum lot size for retail investors is 2 lots, which is 2,000 shares, amounting to ₹2,84,000 at the upper price band.
The tentative allotment date is August 13, 2025.
The registrar of the IPO is Kfin Technologies Limited.
As of the disclosures available, there are no reported governance concerns or red flags regarding the company’s leadership or board structure. Investors may refer to the DRHP and audit reports for detailed information.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading